Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD8330

Known as: ARRY-424704, ARRY-704, MEK Inhibitor AZD8330 
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Dihydropyridines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data
Purpose B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies
In human lung cancer, Tripartite motif 65 (TRIM65) is documented as an important regulator in carcinogenesis. Knockdown of TRIM65… Expand
2017
2017
Chemical-biology approach to delineate the mechanism of action of HIV-1 latency reversing agents
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2015
2015
MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation
Conventional high-grade osteosarcoma is the most common primary bone cancer with relatively high incidence in young people… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
[Effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its mechanism].
OBJECTIVE To investigate the effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its… Expand
Review
2014
Review
2014
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Mitogen-activated protein kinases (MAPKs) are a family of ubiquitous eukaryotic signal transduction enzymes which link… Expand
  • figure 1
  • figure 2
  • table 1
2014
2014
[Effect of AZD8330 on proliferation and apoptosis of multiple myeloma cells].
This study was aimed to investigate the effect of MEK inhibitor AZD8330 on proliferation and apoptosis of multiple myeloma IM9… Expand
Review
2013
Review
2013
MEK and the inhibitors: from bench to bedside
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
2013
2013
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
OBJECTIVE This is the first clinical study of the MEK1/2 inhibitor AZD8330 (ARRY-424704). This phase I study defined the maximum… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2009
2009
Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials
The dual-specificity kinases MEK 1/2 play key roles in tumorgenesis by activating the serine/threonine kinases ERK 1/2. These… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE